ABL2 siRNA Set I(A04-911)
FOR BULK ORDER REQUESTS PLEASE CONTACT US
Description :ABL2 is a pool of three individual synthetic siRNA duplexes designed to knock-down human ABL2 mRNA expression. Each siRNA is 19-25 bases in length.
Specificity :ABL2 siRNAs are designed to specifically knock-down human ABL2 expression.
Formulation :The siRNAs are supplied as a lyophilized powder and shipped at room temperature.
Reconstitution Protocol :Briefly centrifuge the tubes (maximum RCF 4,000g) to collect lyophilized siRNA at the bottom of the tube. Resuspend the siRNA in 50 ul of DEPC-treated water (supplied by researcher), which results in a 1x stock solution (10 uM). Gently pipet the solution 3-5 times to mix and avoid the introduction of bubbles. Optional: aliquot 1x stock solutions for storage.
Storage and Stability :The lyophilized powder is stable for at least 4 weeks at room temperature. It is recommended that the lyophilized and resuspended siRNAs are stored at or below -20oC. After resuspension, siRNA stock solutions ≥2 uM can undergo up to 50 freeze-thaw cycles without significant degradation. For long-term storage, it is recommended that the siRNA is stored at -70oC. For most favorable performance, avoid repeated Handling and multiple freeze/thaw cycles.
Format :Lyophilized powder
Gene Aliases :ARG; ABLL
Scientific Background :ABL2 (or ARG) is a nonreceptor cytoplasmic tyrosine kinase which is closely related to but distinct from ABL1. The similarity of ABL1 and ABL2 includes the tyrosine kinase domains and extends amino-terminal to include the SH2 and SH3 domains. ABL2 is involved in translocation with the ETV6 gene in human leukemia and has an altered expression in several human carcinomas (1). Two isoforms of ABL2 with different N-termini (1A and 1B) have been identified. The C-terminal domain of ABL2 contains two F-actin-binding sequences that perform a number of actions related to cell morphology and motility by interacting with actin filaments (2).
1. Barila, D. et al : An intramolecular SH3-domain interaction regulates c-Abl activity. Nature Genet. 18: 280-282, 1998.
2. Griesinger, F. et al: Identification of an ETV6-ABL2 fusion transcript in combination with an ETV6 point mutation in a T-cell acute lymphoblastic leukaemia cell line. Br J Haematol. 2002 Nov;119(2):454-8.
Product Sheets (By Lot #) :
Research Areas :Cancer, Cell Cycle, Cytoplasmic Tyrosine Kinases, Inflammation, Invasion/Metastasis, Neurobiology, Cancer, Neurobiology, Inflammation, Cell Cycle, Invasion/Metastasis, Cytoplasmic Tyrosine Kinases